Urinary Markers in Bladder Cancer

European Urology

Volumn 53, Issue 5, 2008, Pages 909-916

  Vrooman, Olaf P J ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Markers; Urothelial cell carcinoma

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYALURONIC ACID; HYALURONIDASE; NUCLEAR MATRIX PROTEIN 22; PROTEIN BLCA 1; PROTEIN BLCA 4; SOMATOMEDIN RECEPTOR; SURVIVIN; TELOMERASE; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLADDER CANCER; CANCER GRADING; CYSTOSCOPY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 41149133021     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.12.006     Document Type: Review

References (59)

1. van Rhijn B.W.G., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
2. Lokeshwar V.B., Habuchi T., and Grossman B. Bladder tumor markers beyond cytology: International Consensus on bladder tumor markers. Urology 66 Suppl 1 (2005) 35-63
3. Jones J. DNA-based molecular cytology for bladder cancer surveillance. Urology 67 3 Suppl 1 (2006) 35-45
4. Marin-Aguilera M., Mengual L., Ribal M.J., et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet 173 (2007) 131-135
5. Moonen P.M.J., Merkx G.F.M., Peelen P., Karthaus H.F.M., Smeets D.F.C.M., and Witjes J.A. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51 (2007) 1275-1280
6. Skacel M., Fahmy M., Brainard J., et al. fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients ith bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
7. Sarosdy M., Schellhammer P., Bobinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
8. Halling K., King W., Sokolova I., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768-1775
9. Veeramachaneni R., Nordberg M., Shi R., Herrera G., and Turbat-Herrera E. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 28 (2003) 301-307
10. Kipp B., Karnes R., and Brankley S. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 (2005) 401-404
11. Mao L., Schoenberg M., Scicchiatano M., et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271 (1996) 659-662
12. Turyn J., Matuszewski M., and Schlichtholtz B. Genomic instability analisis of urine sediment versus tumor tissue in transitional cell carcinoma of the urinary bladder. Oncol Rep 15 (2006) 259-265
13. Little B., Hughes A., Young M., and O'Brien A. Use of polymerase chain reaction analysis of urine DNA to detect bladder carcinoma. Urol Oncol 23 (2005) 102-107
14. Frigerio S., Padberg B., Strebel R., et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 121 (2007) 329-338
15. Vriesema J., Atsma F., Kiemeney L., Peelen W., Witjes J., and Schalken J. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58 (2001) 367-371
16. Mian C., Pycha A., Wiener H., et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161 (1999) 1486-1489
17. Pfister C., Chautard D., Devonec M., et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169 (2003) 921-924
18. Schmitz-Dräger B.J., Beiche B., Tirsar L.-A., Schmitz-Dräger C., Bismarck E., and Ebert T. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 51 (2007) 1582-1588
19. Mian C., Maier K., Comploj E., et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 108 (2006) 60-65
20. Glas A., Roos D., Deutekom M., Zwinderman A., Bossuyt P.M., and Kurth K.H. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169 (2003) 1975-1982
21. Sanchini M., Gunelli R., Nanni O., et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294 (2005) 2052-2056
22. Bravaccini S., Sanchini M., Granato A., et al. Urine telomerase activity for the detection of bladder cancer in females. J Urol 178 (2007) 57-61
23. Lokeshwar V., Cerwinka W., and Lokeshwar B. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 65 (2005) 2243-2250
24. Lokeshwar V., Rubinowicz D., Schroeder G., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276 (2001) 1922-1932
25. Pham H., Block N., and Lokeshwar V. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 57 (1997) 778-783
26. Lokeshwar V., Obek C., Pham H., et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163 (2000) 348-356
27. Lokeshwar V., Schroeder G., Selzer M., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95 (2002) 61-72
28. Eissa S., Kassim S., Labib R., et al. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103 (2005) 1356-1362
29. Hautmann S., Toma M., Lorenzo Gomez M.F., et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 46 (2004) 466-471
30. Schroeder G., Lorenzo-Gomez M., Hautmann S., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 172 (2004) 1123-1126
31. Passerotti C.C., Bonfim A., Martins J.R.M., et al. Urinary hyaluran as a marker for the precence of residual transitional cell carcinoma of the urinary bladder. Eur Urol 49 (2006) 71-75
32. Grossman H., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816
33. Grossman H., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
34. ® test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51 (2007) 403-408
35. Shariat S., Marberger M., Lotan Y., et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 176 (2006) 919-926
36. Meyers-Irvin J., Van Le T., and Gertzenberg R. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res 65 (2005) 7145-7150
37. Van Le T., Miller R., Barder T., Babjuk M., Potter D., and Gertzenberg R. Highly specific urine-based marker of bladder cancer. Urology 66 (2005) 1256-1260
38. Konety B., Nguyen T., Dhir R., et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 6 (2000) 2618-2625
39. Meyers-Irvin J., Landsittel D., and Gertzenberg R. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 174 (2005) 64-68
40. Southgate J., Harnden P., and Trejdosiewicz L.K. Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications. Histol Histopathol 14 (1999) 657-664
41. Hakenberg O., Fuessel S., Richter K., et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64 (2004) 1121-1126
42. Pariente J., Bordenave L., Jacob F., et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 163 (2000) 1116-1119
43. Andreadis C., Touloupidis S., Galaktidou G., Kortsaris A., Boutis A., and Mouratidou D. Serum CYFRA21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 174 (2005) 1771-1776
44. Pariente J., Bordenave L., Michel P., Latapie M., Ducasspu D., and Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 158 (1997) 338-341
45. Nisman B., Barak V., Shapiro A., Golijanin D., Peretz T., and Pode D. Evaluation of urine Cyfra 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94 (2002) 2914-2922
46. Fernandez-Gomez J., Rodríguez-Martínez J.J., Escaf Barmadah S., et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 51 (2007) 1267-1274
47. Black P., Brown G., and Dinney C. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 35 (2006) 5528-5534
48. Moussa O., Abol-Enein H., Bissada N., Keane T., Ghoneim M., and Watson D. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 175 (2006) 2312-2316
49. Dabrowski A., Filip A., and Zgodzinski W. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 42 (2004) 169-172
50. Shariat S., Ashfaq R., Karakiewicz P., Saeedi O., Sagalowsky A., and Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109 (2007) 1106-1113
51. Weikert S., Christoph F., Schrader M., Krause H., Miller K., and Müller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116 (2005) 100-104
52. Shariat S., Casella R., Khoddami S., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004) 626-630
53. Schultz I.J., Wester K., Straatman H., et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 51 (2007) 416-423
54. Rotterud R., Nesland J., Berner A., and Fossa S. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 95 (2005) 1344-1350
55. Brandau S., and Bohle A. Molecular and genetic basis of carcinogenesis. Eur Urol 39 (2001) 491-497
56. Litlekalsoy J., Vatne V., Hostmark J., and Laerum O. Immunohistochemical markers in urinary bladder carcinomas from parafin-embedded archival tissue after storage for 5-70 years. BJU Int 99 (2007) 1013-1019
57. Mueller J., von Eggeling F., Driesch D., Schubert J., Melle C., and Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 47 (2005) 885-894
58. Munro N., Cairns D., Clarke P., et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 119 (2006) 2642-2650
59. Talwar R., Sinha T., Karan S., et al. Voided urinary cytology in bladder cancer: is it time to review the indications?. Urology 70 (2007) 267-271